Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 2;12(4):860. doi: 10.3390/cancers12040860

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Immunostaining for calcium-sensing receptor (CaSR) (A,C,E) and chromogranin (B,D,F) on sequential slides. Both markers are expressed in the same areas of normal prostate tissue (A,B, ×10; in inset ×40) and metastatic castration resistant prostate cancerv (MCRPC) (C,D, ×5; in inset ×40). In case of mixed neuroendocrine prostate cancer (NEPC), only the neuroendocrine (NE) component expressed both CaSR and chromogranin (E,F, ×5; in inset ×40). (G). Double immunostaining showing co-localization of CaSR and chromogranin in MCRPC. Cytoplasmic expression of chromogranin is shown as red; membranous staining of CaSR is shown as green. In some cells, CaSR was expressed without chromogranin staining (×60). (H). Kaplan-Meier overall survival in MCRPC patients, according to CaSR staining (p = 0.004).